Cargando…
The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis
BACKGROUND: The balance between Th17 cells and regulatory T (Treg) cells has been shown to play an important role in the development of rheumatoid arthritis (RA). Recent studies have shown that treatment with abatacept (ABT) or tocilizumab (TCZ) affects Th17 and Treg cell populations. Although not u...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947268/ https://www.ncbi.nlm.nih.gov/pubmed/27421886 http://dx.doi.org/10.1186/s12891-016-1137-1 |
_version_ | 1782443144804040704 |
---|---|
author | Tada, Yoshifumi Ono, Nobuyuki Suematsu, Rie Tashiro, Satoko Sadanaga, Yuri Tokuda, Yukiko Ono, Yukihide Nakao, Yoshinobu Maruyama, Akihito Ohta, Akihide Koarada, Syuichi |
author_facet | Tada, Yoshifumi Ono, Nobuyuki Suematsu, Rie Tashiro, Satoko Sadanaga, Yuri Tokuda, Yukiko Ono, Yukihide Nakao, Yoshinobu Maruyama, Akihito Ohta, Akihide Koarada, Syuichi |
author_sort | Tada, Yoshifumi |
collection | PubMed |
description | BACKGROUND: The balance between Th17 cells and regulatory T (Treg) cells has been shown to play an important role in the development of rheumatoid arthritis (RA). Recent studies have shown that treatment with abatacept (ABT) or tocilizumab (TCZ) affects Th17 and Treg cell populations. Although not unanimously accepted, several reports have shown that Treg cells are decreased by ABT and increased by TCZ, and that Th17 cells are decreased by TCZ. To further investigate the effects of ABT and TCZ on the skewing of T cell populations, we analyzed the expression of master regulators genes of helper T cell lineages following ABT/TCZ treatment of RA patients. METHODS: Ten patients treated with ABT and 10 patients treated with TCZ were enrolled. Total RNA was extracted from peripheral blood cells at baseline, and after 12 and 24 weeks of therapy. The expression levels of T-bet, GATA3, Foxp3 and Ror-γt were semi-quantified using real-time PCR. The relative expression levels were expressed as the ratios of two genes (T-bet/GATA3, Foxp3/GATA3, Foxp3/T-bet, Foxp3/Ror-γt, Ror-γt/T-bet, Ror-γt/GATA3), and the changes in these ratios with treatment were determined. RESULTS: The Foxp3/Ror-γt ratio was decreased after ABT therapy (0.67 ± 0.16 at 24 weeks, P = 0.0034) but was increased after TCZ therapy (2.00 ± 1.03 at 24 weeks, P = 0.0013). In addition, the Ror-γt/GATA3 ratio was decreased after TCZ therapy (0.78 ± 0.37 at 24 weeks, P = 0.0008). Except for these ratios, no significant skewing in the expression of these factors was detected. No significant relationship between clinical response to the treatment and change in the ratios of these factors was determined. CONCLUSION: Treatment with TCZ or ABT differently affected the balance between Foxp3 and Ror-γt expression in the peripheral blood of patients with RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-016-1137-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4947268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49472682016-07-17 The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis Tada, Yoshifumi Ono, Nobuyuki Suematsu, Rie Tashiro, Satoko Sadanaga, Yuri Tokuda, Yukiko Ono, Yukihide Nakao, Yoshinobu Maruyama, Akihito Ohta, Akihide Koarada, Syuichi BMC Musculoskelet Disord Research Article BACKGROUND: The balance between Th17 cells and regulatory T (Treg) cells has been shown to play an important role in the development of rheumatoid arthritis (RA). Recent studies have shown that treatment with abatacept (ABT) or tocilizumab (TCZ) affects Th17 and Treg cell populations. Although not unanimously accepted, several reports have shown that Treg cells are decreased by ABT and increased by TCZ, and that Th17 cells are decreased by TCZ. To further investigate the effects of ABT and TCZ on the skewing of T cell populations, we analyzed the expression of master regulators genes of helper T cell lineages following ABT/TCZ treatment of RA patients. METHODS: Ten patients treated with ABT and 10 patients treated with TCZ were enrolled. Total RNA was extracted from peripheral blood cells at baseline, and after 12 and 24 weeks of therapy. The expression levels of T-bet, GATA3, Foxp3 and Ror-γt were semi-quantified using real-time PCR. The relative expression levels were expressed as the ratios of two genes (T-bet/GATA3, Foxp3/GATA3, Foxp3/T-bet, Foxp3/Ror-γt, Ror-γt/T-bet, Ror-γt/GATA3), and the changes in these ratios with treatment were determined. RESULTS: The Foxp3/Ror-γt ratio was decreased after ABT therapy (0.67 ± 0.16 at 24 weeks, P = 0.0034) but was increased after TCZ therapy (2.00 ± 1.03 at 24 weeks, P = 0.0013). In addition, the Ror-γt/GATA3 ratio was decreased after TCZ therapy (0.78 ± 0.37 at 24 weeks, P = 0.0008). Except for these ratios, no significant skewing in the expression of these factors was detected. No significant relationship between clinical response to the treatment and change in the ratios of these factors was determined. CONCLUSION: Treatment with TCZ or ABT differently affected the balance between Foxp3 and Ror-γt expression in the peripheral blood of patients with RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-016-1137-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-16 /pmc/articles/PMC4947268/ /pubmed/27421886 http://dx.doi.org/10.1186/s12891-016-1137-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tada, Yoshifumi Ono, Nobuyuki Suematsu, Rie Tashiro, Satoko Sadanaga, Yuri Tokuda, Yukiko Ono, Yukihide Nakao, Yoshinobu Maruyama, Akihito Ohta, Akihide Koarada, Syuichi The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title | The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title_full | The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title_fullStr | The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title_full_unstemmed | The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title_short | The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
title_sort | balance between foxp3 and ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947268/ https://www.ncbi.nlm.nih.gov/pubmed/27421886 http://dx.doi.org/10.1186/s12891-016-1137-1 |
work_keys_str_mv | AT tadayoshifumi thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT ononobuyuki thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT suematsurie thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT tashirosatoko thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT sadanagayuri thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT tokudayukiko thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT onoyukihide thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT nakaoyoshinobu thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT maruyamaakihito thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT ohtaakihide thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT koaradasyuichi thebalancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT tadayoshifumi balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT ononobuyuki balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT suematsurie balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT tashirosatoko balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT sadanagayuri balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT tokudayukiko balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT onoyukihide balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT nakaoyoshinobu balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT maruyamaakihito balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT ohtaakihide balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis AT koaradasyuichi balancebetweenfoxp3androrgtexpressioninperipheralbloodisalteredbytocilizumabandabataceptinpatientswithrheumatoidarthritis |